Sekisui Chemical (4204) Q3 2026 earnings summary

Executive summary

• Q3 FY2025 net sales reached a record ¥330.1 billion, with 1Q–3Q net sales at ¥959.9 billion, up year-on-year despite market weakness.

• Operating and ordinary profit declined year-on-year, mainly due to a ¥14.9 billion impairment loss in the biorefinery business.

• Profit attributable to owners dropped 30.2% to ¥47.8 billion for 1Q–3Q.

• Share buyback program expanded, with treasury shares repurchased and cancelled to enhance shareholder returns.

• Comprehensive income rose 20.8% year-on-year to ¥79.9 billion, driven by FX gains.

Financial highlights

• 3Q FY2025 net sales: ¥330.1 billion (+¥3.8 billion YoY); 1Q–3Q: ¥959.9 billion (+¥4.6 billion YoY).

• 3Q operating profit: ¥27.5 billion (–¥1.2 billion YoY); 1Q–3Q: ¥72.9 billion (–¥4.5 billion YoY).

• FY2025 forecasts: net sales ¥1,327.9 billion, operating profit ¥110.0 billion, ordinary profit ¥112.0 billion, profit attributable to owners ¥72.0 billion.

• EBITDA forecast for FY2025: ¥168.6 billion, with annual dividend planned at ¥80 per share for the 16th consecutive increase.

• EPS for the period was ¥115.62, down from ¥163.73 in the prior year.

Outlook and guidance

• FY2025 guidance projects record highs in net sales, operating profit, and ordinary profit.

• Full-year net sales forecast revised upward to ¥1,327.9 billion; annual dividend maintained at ¥80 per share.

• Q4 expected to see growth in net sales and operating profit across all segments except Medical.

• Dividend increase planned, with continued focus on steady growth and preparation for the next medium-term plan.